Hi

It's great news! MindBio has received final regulatory, ethics and ministerial approval to start take-home dosing MB22001 in a Phase 2B trial in patients with Major Depressive Disorder.

The mounting evidence for microdosing MB22001 as a scalable, effective and safe treatment for depression is compelling and you can see a summary in the slideshow link below. That is why the company is advancing its microdosing treatment protocol using MB22001 through to Phase 2B clinical trials.

In this Phase 2B trial, a randomised, triple blind and active placebo controlled trial (n=90), half of the patients will be given MB22001 and half will be given an active placebo over an 8 week trial. At the end of the 8 weeks, all clinical trial participants will be offered another 8 weeks on MB22001 to give patients in the placebo group the opportunity to be treated with the drug. It means we will be collecting 16 weeks of data for each clinical trial participant.

View presentation

We thank you for your support and interest in our scientific work.

Click here to view the slideshow.

Stay Well!

JUSTIN HANKA

Chief Executive Officer & Co-Founder

MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)

Follow CEO Justin Hanka on LinkedIn:

https://www.linkedin.com/in/justinhanka/

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true